| dc.contributor.author | Hennessy, Martina | |
| dc.date.accessioned | 2024-01-29T14:23:54Z | |
| dc.date.available | 2024-01-29T14:23:54Z | |
| dc.date.created | 2021 | en |
| dc.date.issued | 2021 | |
| dc.date.submitted | 2021 | en |
| dc.identifier.citation | McEvoy N.L, Clarke J.L, Mc Elvaney O.J, Mc Elvaney O.F, Boland F, Hyland D, Geoghegan P, Donnelly K, Friel O, Cullen A, Collins A.M, Fraughen D, Martin-Loeches I, Hennessy M, Laffey J.G, Mc Elvaney N.G, Curley G.F, A randomised, double-blind, placebo-controlled, pilot trial of intravenous plasma purified alpha-1 antitrypsin for SARS-CoV-2-induced Acute Respiratory Distress Syndrome: a structured summary of a study protocol for a randomised, controlled trial, Trials, 22, 1, 2021 | en |
| dc.identifier.other | Y | |
| dc.description | PUBLISHED | en |
| dc.description.abstract | The primary objective is to demonstrate that, in patients with PCR-confirmed SARS-CoV-2 resulting in
Acute Respiratory Distress Syndrome (ARDS), administration of 120mg/kg of body weight of intravenous
Prolastin®(plasma-purified alpha-1 antitrypsin) reduces circulating plasma levels of interleukin-6 (IL-6). Secondary
objectives are to determine the effects of intravenous Prolastin® on important clinical outcomes including the
incidence of adverse events (AEs) and serious adverse events (SAEs). | en |
| dc.language.iso | en | en |
| dc.relation.ispartofseries | Trials; | |
| dc.relation.ispartofseries | 22; | |
| dc.relation.ispartofseries | 1; | |
| dc.rights | Y | en |
| dc.title | A randomised, double-blind, placebo-controlled, pilot trial of intravenous plasma purified alpha-1 antitrypsin for SARS-CoV-2-induced Acute Respiratory Distress Syndrome: a structured summary of a study protocol for a randomised, controlled trial | en |
| dc.type | Journal Article | en |
| dc.type.supercollection | scholarly_publications | en |
| dc.type.supercollection | refereed_publications | en |
| dc.identifier.peoplefinderurl | http://people.tcd.ie/mhenness | |
| dc.identifier.rssinternalid | 261602 | |
| dc.identifier.doi | http://dx.doi.org/10.1186/s13063-021-05254-0 | |
| dc.rights.ecaccessrights | openAccess | |
| dc.identifier.rssuri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85104507412&doi=10.1186%2fs13063-021-05254-0&partnerID=40&md5=0a2bfa2237ee093ee3273214d3ff84fe | |
| dc.identifier.orcid_id | 0000-0002-2153-5288 | |
| dc.identifier.uri | http://hdl.handle.net/2262/104813 | |
